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Abstract The FRAX calculator is a major achievement in
terms of our understanding of measuring fracture risk. Along
with being an easily accessible web-based tool, it is the only
model based on extensive data on multiple cohorts. FRAX
will help clinicians identify individuals who need osteoporo-
sis treatments, while also screening out those who do not
require osteoporosis treatments. However, FRAX is limited
by a number of factors. Although it is web based, few
physicians have the means to access it. It also assumes that
body mass index and mortality are constant across different
racial and ethnic groups. FRAX is further limited by the
exclusion of variables known to be associated with fracture
risk, lack of dose-response relationships for variables,
increased subsequent fracture risk after initial fracture,
restriction to only one bone mineral density site, racial and
ethnic differences that may influence fracture risk, and
availability of racial and ethnic fracture risk data to be used
in the FRAX calculator. Finally, the values obtained from
FRAX should not take the place of good clinical judgment.
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Introduction
Despite a diverse therapeutic menu and the availability of
dual-energy x-ray absorptiometry, many patients at risk for
osteoporotic fracture are undiagnosed and untreated [1–4].
Bone mineral density (BMD) assessment, although specific,
may not be sensitive for predicting fracture risk. Adding
clinical risk factors that are able to predict fracture
independent of BMD [5–8] may improve our ability to
predict fracture risk.
To improve patient assessment at the primary care level, a
World Health Organization (WHO) task force developed an
algorithm that calculates absolute fracture risk based on
population-based cohorts from Europe, North America, Asia,
and Australia. The algorithm includes the following risk
factors: age [9], prior fracture [10￿], parental history of hip
fracture [11￿], low body weight or body mass index (BMI)
[12], use of glucocorticoids of 5 mg or more for 3 months or
more [13￿], rheumatoid arthritis (RA) [14], current cigarette
smoking [15], excessive alcohol intake of 3 units or more
daily (3 medium glasses of wine or 3 half pints of beer)
[16￿], and secondary osteoporosis [14]. This tool, called the
FRAX tool, calculates the 10-year absolute fracture risk in
individual patients for hip fractures or major osteoporotic
fractures (hip, wrist, humerus, and clinical spine) [17, 18].
Earlier guidelines such as the National Osteoporosis
Foundation (NOF) selected patients for treatment who had
pre-existing hip or spine fracture, or low BMD with clinical
risk factors. These clinical risk factors were not weighted,
and patients with more than one risk factor were weighted
no differently [19, 20]. The use by WHO of combined data
from multiple cohorts with different clinical risk factors has
improved our ability to predict the absolute risk of fracture.
The absolute risk of fracture refers to the individual risk of
fractures over a certain time period [14]. Ten years was
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We had historically defined osteoporosis by bone density
alone, with osteoporosis being a T-score of 2.5 SDs below
peak BMD in female populations and osteopenia, which we
would now term low bone mass, between −1 and −2.5 [21–
24]. With the increased recognition that over half of
individuals in the community with fractures do not have
osteoporosis as defined by BMD, we now separate patients
with low bone mass into those with low risk versus high
risk. Risk factors in the WHO algorithm are required to be
simple, responsive to therapies available, and have been
studied in population cohorts [25].
How Was FRAX Developed?
The WHO task force first reviewed the literature using meta-
analysis to identify risk factors for fracture independent of
BMD. Secondly, a mega-analysis was done by combining
data from 12 cohorts around the world, including studies in
Australia [26, 27], Hiroshima [28, 29], multiple studies in
Europe such as EVOS/EPOS [30–32], EPIDOS [33],
Gothenburg I [34, 35] and II [36], Rotterdam [7], Sheffield
[37], Kuopio in Finland [38], the OFELY study in France [8,
39], as well as CaMos in Canada [40] and Rochester in the
United States [41, 42].
The global cohort consisted of approximately 250,000
person years, approximately 60,000 patients, and 5000
fractures. Using this analysis, the eight candidate risk factors
were proposed. To be considered, each of these risk factors
needed to be validated in multiple populations, adjustable for
age,sex,andtypeoffracture,intuitive,amenabletotherapeutic
manipulation, and readily accessible for primary care practi-
tioner [18, 25, 43]. Thus, factors such as calcium deficiency
and risk of falling or vitamin D levels, which would not be
easy for primary care physicians to measure, were not
included. The clinical risk factors may be added, but the
sum varies depending on the risk factors added because of
differing weights. The risk factors improve prediction of
fracture risk by improving the gradient of risk [44￿￿]. The
addition of clinical risk factors is most valuable for younger
women and least valuable for those who are elderly. For each
country we add country-specific fracture incidence rates.
In this model, we use 10-year probability of fracture not
relative risk, because relative risk decreases with age. For
example, by 80 years of age, the relative risk of fracture
comparedwithother80-year-oldwomenwithaT-scoreof−2.5
is reduced because many women this age are at a high risk for
fracture independent of BMD. Similarly, lifetime fracture risk
is not used because it begins to decline at 70 years of age
because of competing risk of death.
The risk of different clinical fractures is also combined in
this model, not by simply adding them but by weighting the
clinicalfracturebasedonmorbidityand mortalityusingutility
measurement compared with the utility of a so-called “hip
fracture,” reducing fracture risk to a common currency [45].
Assumptions About FRAX
The FRAX model requires certain assumptions that are used
in the development of new country-specific models: 1) The
relationship between BMI and mortality is constant across
different racial and ethnic groups. 2) In many countries, we
may have data on the incidence of hip fracture but no data on
nonvertebral fracture and vertebral fractures. Data on these
fractures are estimated based on the incidence of hip fracture
using US Caucasians as the reference from the NHANES.
However, this ratio may not apply across all racial and ethnic
groups in countries and regions of the world.
Validation of FRAX
The FRAX model has been validated in 11 cohorts [25]. No
randomized controlled trial data focusing on prevention of
fractures in patients who were included based on FRAX are
available. However, in post hoc analysis of intervention
studies with clodronate [46] and bazedoxifene [47, 48],
antifracture efficacy has been shown in patients selected high
risk according to FRAX but not low risk. However, such
results were not found in the post hoc analysis of raloxifene
studies [49]. Further studies will be needed to evaluate the
ability of treatment to reduce fracture risk in subjects at high
risk for fractures based on FRAX in the absence of a
prevalent fracture or fracture with BMD.
When Not to Use FRAX
FRAX does not replace good clinical judgment by the health
care practitioner. For example, in patients with multiple
fractures, it is anticipated the clinician would increase his or
herestimateoffracturerisk.Similarly,theclinicianshoulduse
judgement for individuals based on corticosteroid dose and
duration, multiple secondary osteoporosis risk factors, or
amount of smoking and alcohol use. FRAX should not be
used in individuals currently taking osteoporosis therapy.
Use of Interventional Thresholds
How do we set interventional thresholds based on FRAX?
There are two possible ways. In the United States, we use
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50]. We continue to state that patients with a T-score of less
than −2.5 in the hip or spine have osteoporosis but also ask
the patients who are osteopenic or low bone mass whether
they are at high risk or low risk based on FRAX, where we
stated that 3% risk of hip fracture is high risk and 20% risk
of major osteoporotic fracture is high risk [21, 23, 50]. In
other countries, FRAX is used alone to estimate risk
independent of any given BMD threshold.
Strengths of FRAX
FRAX is a major achievement in terms of our understand-
ing of measuring fracture risk. It is the only model based on
extensive data on multiple cohorts with and without BMD
that has been validated in additional cohorts [17]. FRAX
will help clinicians identify individuals who need osteopo-
rosis treatment and also individuals who do not need
osteoporosis treatment. FRAX is now widely accepted in
treatment decisions such as the NOF guidelines. The
probability of fracture can now be estimated based on
clinical risk factors and BMD globally. The model uses
primary data to use weighted clinical risk facture and is
calibrated to local epidemiology of fracture and mortality
[18]. It is now available worldwide in Asia, in China, Hong
Kong, Japan, South Korea, Taiwan, and Lebanon; in Europe
inAustria,Belgium,Finland,France,Germany,Hungary,The
Netherlands, Italy, Spain, Sweden, Switzerland, Turkey, and
the United Kingdom; in North America in the United States;
in Latin America in Argentina, Columbia, and Mexico; and in
Oceania in Australia and New Zealand. It is available in 11
languages.
FRAX may be useful as inclusion criteria in designing
future clinical trials in which fracture is an outcome. It is
important to note that background risk of fracture in FRAX
will vary between populations. Therefore, it is important to
calculate population-specific individualized FRAX risk and
develop country-specific models. FRAX can be used
dynamically over time in patients whose clinical risk
factors change over time.
Limitations of FRAX
FRAX has multiple limitations:
1. Certain variables were excluded. For example, FRAX
doesnotinclude measurementsthatwouldbedifficultto
obtain by a primary care practitioner—measurements of
physical activity, vitamin D deficiency, bone turnover
markers, or loss of bone mass between sequential BMD
measurements [17, 18]. For example, falls were
explicitly excluded. Reasons given are about lack of
standardized evaluation methods, the lack of data
showing fall prevention measures, and decreased risk
of fractures. However, we do clearly recognize falls as
a risk for fractures independently of bone-related risk
for nonvertebral fractures including hip fractures.
2. FRAX does not take into account dose-response
relationships. For example, FRAX does not make a
difference between single versus multiple fractures,
different doses and duration of glucocorticoid use, and
different doses of units and duration of use of alcohol
or smoking in terms of packs per day. It does not take
into account characteristics for prior fractures such as
number, severity, and type [17, 18, 51].
3. The increased subsequent fracture risk after initial
fracture is considered constant over time in FRAX.
However, observational studies have shown that
subsequent fracture risk fluctuates over time and
may be highest in the first 5 years after initial fracture
[25].
4. FRAX may only be used in untreated patients [19, 20].
5. The BMD input is limited to the femoral neck based
on available population data. FRAX does not account
for individuals who have low lumbar T-score but with
normal femoral neck [19].
6. Patient ascertainment of RA. Individuals may think
they have RA when it really is osteoarthritis [25].
7. Poor definition of secondary osteoporosis. The current
model assumes that the additional risk of secondary
osteoporosis is mediated largely through BMD. If
BMD is entered, secondary osteoporosis does not
change the calculated risk. Furthermore, multiple risk
factors account for secondary osteoporosis. FRAX
does not take into account combinations of multiple
risks such as hypothyroidism and malabsorption due
to gastric bypass [51].
8. Internet access. Not all physicians have Internet access
in their examination rooms at this time [25, 43].
9. Relationship between BMI and mortality. FRAX
assumes that the relationship between BMI and
mortality in all races and ethnic groups are similar.
There are no data to know if this is true for African
Americans, Hispanics, and Asians [52].
10. There may be racial or ethnic differences that
influence fracture risk not taken into account by
FRAX. When BMD is absent, fracture risk in
Hispanics and African Americans appears to be
underestimated [52].
11. Variability in fracture rates. FRAX assumes that the
variability in fracture rates is similar across race and
ethnic groups in the United States. The variability in
hip fracture rates in Hispanics is greater than in
Caucasians in the United States [52].
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FRAX may be used for randomized control trials as
inclusion criteria for following fracture risk over time.
Alternatives of FRAX
Do we need all the clinical risk factors in FRAX?
Cummings and Melton [53] bring out in recent papers that
there are several strong factors, as do Black et al. [54], that
may well account for most of fracture risk such as BMD or
BMI, age, and past medical history of fracture. Several
alternatives of FRAX exist such as the Canadian Osteo-
porosis Society [55], the Nguyen algorithm [56], and the
Dutch algorithm [57]. These risk factor algorithms depend
o nas m a l l e rn u m b e ro fc l i n i c a lr isk factors. They are often
only valid and include other additional factors that may
n o tb ei n c l u d e di nF R A Xs u c ha sf a l l s .T h e ya r eo f t e n
validated only in a given observational study or given
cohort and at this time may not have generalized
applicability. They need to be validated in different
countries.
Statistical Literacy
Communication about FRAX risk depends on the patient’s
understanding of the statistical concept of risk, which has
been called statistical numeracy [58]. Statistical numeracy
is essential if our patients are to understand health-related
risks and make informed medical decisions. Statistical
numeracy is part of a more general concept of qualitative
and quantitative mathematical literacy.
In a recent study by Galesic et al. [58]u s i n ga
numeracy scale, a large gap was identified in the United
States between patients with lower and higher educational
levels. Although a college-educated American could
answer 83% correctly, those with less than high school
education could only answer 40%. For example, 20% of
US participants could not say which of the following
numbers represented the biggest risk of disease: 1%, 5%,
or 10%, and about 76.5% of US participants could not
transform 1 in 1000 to a percentage. Even physicians had
difficulty, with 25% of physicians unable to correctly
convert this into a percentage.
Impact of FRAX Information
It is likely that the advent of FRAX will result in
minimal change in treatment of women with osteoporosis
as defined by fracture or low T-score. However, it is very
likely women with low bone mass and low risk will be
less likely to be treated. We can hypothesize those
younger women who are told they have osteopenia but
are at low risk for major osteoporotic fracture would not
be willing to take a medicine that would then reduce
their risk by a half. In one study by Ettinger et al. [59],
physicians who are shown clinical data and information on
absolute risk are less likely to prescribe medication than
when shown only clinical data.
There have been no studies as yet to confirm whether the
use of FRAX will improve outcomes. If we look at risk
estimation in other disease states such as coronary heart
disease (CHD), we see that global risk estimation for
coronary artery disease calculated by combining risk factors
along with accompanying education increased the accuracy
of perceived risk and increased intent to start therapy. This
intervention reduced predicted CHD by −0.2% to 2% over
10 years when given repeatedly over time. Therefore, it is
likely that providing global risk information to patients at
only one point in time may well be relatively ineffective
[60]. We should thus consider repeating FRAX information
over time. The effect on FRAX on distal outcomes is less
clear. It may depend on the intensity of accompanying
interventions.
FRAXhas recentlybeen added to bonedensity software. It
is currently on a calculator in Japan, a CD in Poland, and has
now appeared on the US iPhone. The FRAX website has
about 60,000 hits daily, with total cumulative hits of about
200,000,000.Itisavailableonthewebsitehttp://www.shef.ac.
uk, and also now on PDA and simple paper-based models on
a FRAX calculator through the International Osteoporosis
Foundation.
Conclusions
The FRAX calculator is a major tool for identifying
patients who may need osteoporosis treatments as well as
identifying patients who may not need osteoporosis
treatments. Although FRAX has utility as a clinical tool,
it also has multiple limitations that may affect fracture
risk calculations. Despite these limitations, FRAX is
being used globally by physicians to assess fracture risk.
The use of FRAX, although currently limited, will
increase once incorporated into BMD software and
PDAs.
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